98%
921
2 minutes
20
Background: There has been conflicting reports on the effect of third generation aromatase inhibitors on cognition in estrogen-deficient states. Since aromatase inhibitors themselves cause estrogen deprivation, the present work was designed to evaluate the comparative effect of three aromatase inhibitors on behavioral measures of learning and memory in female mice. Further, in view of the reports of estrogen and Wnt signaling pathway in cognition, the role of two Wnt signaling antagonists (dickkopf-1 and sclerostin) in mediation of cognitive effects of aromatase inhibitors was evaluated.
Methods: Three behavioral paradigms were used for evaluating cognitive functions viz. Morris water maze, active avoidance learning and spontaneous alternation behavior following 10-15days of administration with aromatase inhibitors and the levels of dickkopf-1 and sclerostin were evaluated in hippocampus of female mice.
Results: Anastrozole and letrozole (but not exemestane) impaired learning and memory as indicated by increase in escape latency and path length during spatial acquisition, reduction of % quadrant dwell time in Morris water maze, reduction of % avoidance and increase in escape responses in active avoidance learning and decrease in % alternation in a cross maze. The behavioral effects correlated well with the levels of dickkopf-1 and sclerostin in the mouse hippocampus. The highest impairment in learning and memory occurred with letrozole followed by anastrozole while exemestane was without such effects.
Conclusion: The present study demonstrates that aromatase inhibitors have adverse impact on cognition. Furthermore, modulation of Wnt signaling following estrogen depletion possibly contributed to observed effects in case of anastrozole and letrozole.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pharep.2017.06.002 | DOI Listing |
Front Endocrinol (Lausanne)
September 2025
Pediatric Endocrinology Department, Obesity, Endocrine and Metabolism Center, King Fahd Medical City, Riyadh, Saudi Arabia.
McCune-Albright syndrome (MAS) is a rare genetic disorder characterized by a triad of café-au-lait spots, fibrous dysplasia, and hyperfunctioning endocrinopathies, resulting from a mosaic mutation in the guanine nucleotide-binding protein (GNAS) gene. This case report presents the long-term follow-up of an eight-year-old girl diagnosed with MAS, who first presented at 22 months of age with skin pigmentation, hyperthyroidism, and precocious puberty, later developing additional features such as fibrous dysplasia and growth hormone excess. This complex presentation of MAS-featuring more than two hyperfunctioning endocrinopathies along with fibrous dysplasia-has rarely been described in the literature.
View Article and Find Full Text PDFMed Sci Sports Exerc
September 2025
VivoSense, Inc., Newport Coast, CA.
Endocrine therapies for breast cancer (BC) (i.e., selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AI)) lower the risk for cancer recurrence but are linked to an increased risk of type 2 diabetes (T2D).
View Article and Find Full Text PDFJ Ovarian Res
September 2025
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Background: Polycystic ovary syndrome (PCOS) is a complex disorder characterized by various reproductive, metabolic, and endocrine abnormalities. Hyperandrogenism is a key feature of PCOS that significantly impacts ovarian function. However, its effects on granulosa cells (GCs) function for estrogen production in PCOS remains limited.
View Article and Find Full Text PDFESMO Open
September 2025
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, USA.
Background: All three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, and abemaciclib) plus aromatase inhibitor (AI) significantly prolonged progression-free survival (PFS) versus placebo plus AI and achieved a similar reduction in risk of disease progression in randomized controlled trials (RCTs) evaluating first-line (1L) treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). To date, there have been no head-to-head RCT data comparing CDK4/6i, and most real-world comparative effectiveness studies were limited by small sample sizes and/or short follow-up. In this analysis, we compared real-world PFS (rwPFS) in patients with HR-positive/HER2-negative mBC receiving 1L CDK4/6i plus AI in United States routine clinical practice.
View Article and Find Full Text PDFEndokrynol Pol
September 2025
Department of Reproductive Health, Center of Postgraduate Medical Education, Warsaw, Poland.
Functional hypogonadism is a syndrome characterized by low testosterone levels and clinical features of hypogonadism without organic disease of the hypothalamus-pituitary-gonadal axis. It is most prevalent among middle-aged and older men as late-onset hypogonadism as well as in a wide range of conditions such as obesity, type 2 diabetes, opioid use, or exogenous steroid abuse. As a potentially reversible condition, lifestyle modifications are the basis of initial management of functional hypogonadism.
View Article and Find Full Text PDF